[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1994007471A1 - Ibuprofen-caffeine combinations - Google Patents

Ibuprofen-caffeine combinations Download PDF

Info

Publication number
WO1994007471A1
WO1994007471A1 PCT/US1993/008896 US9308896W WO9407471A1 WO 1994007471 A1 WO1994007471 A1 WO 1994007471A1 US 9308896 W US9308896 W US 9308896W WO 9407471 A1 WO9407471 A1 WO 9407471A1
Authority
WO
WIPO (PCT)
Prior art keywords
ibuprofen
lysine
caffeine
salt
enhancement
Prior art date
Application number
PCT/US1993/008896
Other languages
French (fr)
Inventor
Robert T. Sims
William Slivka
Robert Mcmahon
Original Assignee
Merck & Co., Inc.
Mcneil-Ppc, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co., Inc., Mcneil-Ppc, Inc. filed Critical Merck & Co., Inc.
Priority to EP93922264A priority Critical patent/EP0663819A4/en
Priority to JP6509126A priority patent/JPH08501796A/en
Priority to AU51328/93A priority patent/AU5132893A/en
Publication of WO1994007471A1 publication Critical patent/WO1994007471A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • NSAID non-steroidal anti-inflammatory drugs
  • NSAIDs have been utilized in the treatment of pain/inflammation and a number of other symptoms including stiffness that are associated with painful conditions affecting muscles, bones, and joints.
  • NSAIDs have been prescribed to relieve back pain, gout, menstrual pain, headaches, mild pain following surgery, and pain from soft tissue injuries such as sprains and strains.
  • NSAIDs are within the broader class of non- narcotic analgesics which also includes acetylsahcyclic acid (aspirin) and acetaminophen.
  • NSAIDs, except for acetaminophen are generally considered to exert their effect by blocking the production of prostaglandins at the site of pain, irritation or injury so that the pain signal does not reach the brain.
  • Ibuprofen (2-(4-isobutylphenyl)propionic acid) is a well known and commonly employed NSAID.
  • Amino acid salts of racemic ibuprofen Including the lysine or arginine salt are also known pain relievers. See U.S. Pat. No. 4,279,926.
  • S-ibuprofen also known as (-f-)-ibuprofen or dexibuprofen
  • Caffeine is a well known xanthine alkaloid and is used in a number of foods and medicines.
  • the Xanthines including caffeine, are known to stimulate the central nervous system, induce relaxation of smooth muscle constrictions of the smaller bronchi and other smooth muscles, cause dilation of the small pulmonary arteries, and induce stimulation of cardiac muscle with increased cardiac output and the promotion of mild diuresis. It has been postulated that these actions may be related to the antagonism of adenosine receptors.
  • compositions for use in the treatment of pain and inflammation comprising:
  • This invention is also directed to a method of treating pain and inflammation in mammals, including humans, in need thereof, comprising administering to such organism:
  • This invention is further directed to a method of eliciting an onset hastened and enhanced response for the treatment of pain and inflammation in mammals, including humans, in need thereof, comprising administering to such organism: (i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)- lysine; and (ii) an amount effective in enhancement of pain relief of caffeine.
  • Substantially free of (R)-ibuprofen means that the ratio of (S)-ibuprofen to (R)-ibuprofen is at least 90:10.
  • Salts of (S)-ibuprofen include pharmaceutically acceptable salts such as alkali metals (sodium or potassium), alkaline earth metals (calcium), or salts with other metals such as magnesium, aluminum, iron, zinc, copper, nickel or cobalt.
  • compositions of the instant invention further include the amino acid salts, particularly the basic amino acids such as lysine or arginine.
  • amino acid salts particularly the basic amino acids such as lysine or arginine.
  • Specifically included within the composition of the instant invention is (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)- lysine.
  • mammals or mammalian organism includes but is not limited to man, dog, cat, horse and cow.
  • (S)-ibuprofen may be prepared following the procedures disclosed in U.S. Patent 4,877,620.
  • Metal salts of ibuprofen may be obtained by contacting a hydroxide, or carbonate with ibuprofen.
  • Amino acid salts of ibuprofen may be obtained by contacting an amino acid in solution with ibuprofen.
  • 4,994,604 describes a process for the formation and resolution of (S)-ibuprofen-(S)-lysine that employs preferential crystallization to separate a pair of diastereomeric salts, (S)-ibuprofen-(S)-lysine and (R)-ibuprofen-(S)-lysine.
  • the basic procedure involves (a) contacting (R),(S)-ibuprofen and (S)-lysine in an aqueous-organic solvent mixture; (b) separating any suspended solid from the mixture; and (c) cooling the clear mixture until the mixture is supersaturated with respect to each of the (S)-ibuprofen-(S)-lysine and (R)-ibuprofen-(S)-lysine salts; (d) contacting the supersaturated mixture with a slurry of (S)-ibuprofen-(S)-lysine in an aqueous-organic solvent; and (e) separating the formed crystalline (S)-ibuprofen-(S)-lysine.
  • racemic ibuprofen starting material is mixed with an organic solvent that is miscible with water.
  • the (S)- lysine is mixed with water and the ibuprofen and lysine solutions are combined.
  • the mixture is agitated for a time period sufficient to crystallize all the salts, if any, in excess of the solubility limit.
  • the suspended salts are separated to obtain a clear mother liquor which is generally saturated with respect to the diastereomeric salts (S)- ibuprofen-(S)-lysine and (R)-ibuprofen-(S)-lysine. Filtration may be employed to effect the separation.
  • the liquor is then cooled to a temperature at which it is supersaturated with respect to each of the diastereomeric salts. It is preferred that the liquor be cooled to the point at which maximum supersaturation is obtained with respect to each salt without nucleation of either crystallizable species.
  • the temperature of the mother liquor must be lowered by about 5° C to reach maximum supersaturation without precipitation of either salt.
  • the degree of cooling will depend on the particular solvent composition.
  • the supersaturated liquor is then passed into a vessel containing a slurry of (S)-ibuprofen-(S)-lysine, hereafter referred to as the (S,S) salt, in the same solvent system employed above for the mixture of racemic ibuprofen and (S)-lysine.
  • the (S,S) salt crystals acting as a seed the supersaturation of the (S,S)-salt in the feed liquor is released by the growth of further crystals of the (S,S)- salt.
  • compositions of the present invention are useful in the rapid and enhanced treatment of pain and inflammation.
  • the (S)-ibuprofen-(S)-lysine combined with caffeine is useful for the treatment of pain, and inflammation.
  • the utilization of (S)-ibuprofen and in particular (S)-ibuprofen-(S)-lysine in an analgesic/caffeine combination offers significant advantages over the combination of racemic ibuprofen and caffeine or (S)-ibuprofen and caffeine.
  • (S)-ibuprofen and in particular the lysine salt of (S)- ibuprofen provides a faster onset of pain and inflammation relief and an enhanced degree of relief compared to racemic ibuprofen.
  • These benefits contribute to overall enhanced and faster relief of symptoms associated with headaches and other aches and pains when the (S)- ibuprofen -(S)-lysine is combined with a xanthine derivative such as caffeine.
  • the absence or reduction of (R)-ibuprofen also provides significant benefits.
  • the allergic contraindications sometimes associated with ibuprofen administration are absent or reduced in a (R)-ibuprofen- free or substantially -free composition.
  • An additional advantage may be that less metabolic energy will be used to convert the inactive (R)- ibuprofen to the active (S)-ibuprofen.
  • a reduced burden may be placed on the urogenital system since administration of the pure (S)-ibuprofen eliminates the need to excrete the (R)-ibuprofen or its metabolites.
  • the absence of the (R)-enantiomer also reduces or eliminates the incorporation of this molecule into fatty tissue.
  • the renal burden and renal toxicities sometimes associated with racemic ibuprofen therapy may be reduced or eliminated in a (S)-ibuprofen composition that is substantially free of the (R) enantiomer.
  • Caffeine and xanthine alkaloids are known in the art and may be used in combination with (S)-ibuprofen (S)-lysine. Caffeine is well tolerated and has minimal side effects and thus advantageously may be used in the present invention in combination with (S)-ibuprofen (S)- lysine.
  • the composition of (S)-ibuprofen-(S)-lysine with caffeine provides a combination which simultaneously and selectively provides enhanced relief from headaches, pain, and inflammation. This combination also has an advantage under circumstances where a mammalian organism requires enhanced pain relief and wakefulness or mental altertness.
  • inactive enantiomers particularly (R)- ibuprofen provides for significant size and weight advantages in a combination dosage form, particularly a sustained release dosage form.
  • a sustained release dosage of ibuprofen may have required 800 to 1000 mg
  • the employment of (S)-ibuprofen-(S)-lysine reduces the weight to 400 to 500 mg, and provides for a more practical size tablet for an ibuprofen/caffeine combination.
  • An effective amount of (S)-ibuprofen, or a salt thereof, for use in a unit dose composition of this invention may range from 50-800 mg of (S)-ibuprofen.
  • the preferred amount of (S)-ibuprofen is about 100 to 400 mg.
  • the amount of a salt such as (S)-ibuprofen-(S)-lysine is determined based on the amount of (S)-ibuprofen contained therein.
  • Caffeine is advantageously used in the present invention in combination with (S)-ibuprofen-(S)-lysine.
  • the amount of caffeine used in the present invention in humans may range from 20 to 400 milligrams (mg).
  • 32 to 65 mg is administered in combination with 100 to 400 mg of (S)-ibuprofen (S)-lysine.
  • the combination claimed in the instant invention is advantageously admimstered orally.
  • the claimed combination may be administered intravenously in a suitable dosage within the limits described for oral treatment.
  • the present composition may be administered in the form of tablets, caplets, gelcaps, capsules, elixirs, syrups, or suspensions.
  • the active ingredients may be admixed with a pharmaceutically acceptable diluent such as lactose, sucrose, cellulose, dicalcium phosphate, calcium sulfate, mannitol, and, in a liquid composition, ethyl alcohol.
  • Acceptable emulsifying or suspending agents such as PVP, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, guar gum, agar, bentonite, carboxymethylcellulose sodium, polyethylene glycol and waxes, may also be admixed with the active components.
  • lubricants such as magnesium stearic acid talc or magnesium stearate, and disintegrators or superdisintegrators such as starch, sodium starch glycolate or cross-linked PVP may also be included.
  • Electrolytes such as dicalcium phosphate, sodium benzoate, sodium acetate and sodium chloride may also be used.
  • the active components may also be formulated in sustained release or effervescent formulations. These formulations depending upon whether they are sustained release or effervescent may be employed in oral, dermal, rectal or vaginal administrations.
  • the sustained release formulations also include layered formulations which provide for distinct release ratio and thus may be more effective in allowing for short and long term relief.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation in mammals, including humans, by administering compositions comprising (i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)-lysine; and (ii) an amount effective in the enhancement of pain relief of caffeine.

Description

TITLE OF THE INVENTION IBUPROFEN-CAFFEINE COMBINATIONS
BACKGROUND OF THE INVENTION
The non-steroidal anti-inflammatory drugs (NSAID) have been utilized in the treatment of pain/inflammation and a number of other symptoms including stiffness that are associated with painful conditions affecting muscles, bones, and joints. NSAIDs have been prescribed to relieve back pain, gout, menstrual pain, headaches, mild pain following surgery, and pain from soft tissue injuries such as sprains and strains. NSAIDs are within the broader class of non- narcotic analgesics which also includes acetylsahcyclic acid (aspirin) and acetaminophen. NSAIDs, except for acetaminophen, are generally considered to exert their effect by blocking the production of prostaglandins at the site of pain, irritation or injury so that the pain signal does not reach the brain.
Ibuprofen (2-(4-isobutylphenyl)propionic acid) is a well known and commonly employed NSAID. Amino acid salts of racemic ibuprofen Including the lysine or arginine salt are also known pain relievers. See U.S. Pat. No. 4,279,926. Recently, it has been found that a faster onset of pain relief and an enhanced analgesic response can be obtained by utilizing the single enantiomer (S)-ibuprofen (also known as (-f-)-ibuprofen or dexibuprofen) rather than the racemic mixture of ibuprofen. See U.S. Patent 4,877,620.
Caffeine is a well known xanthine alkaloid and is used in a number of foods and medicines. The Xanthines, including caffeine, are known to stimulate the central nervous system, induce relaxation of smooth muscle constrictions of the smaller bronchi and other smooth muscles, cause dilation of the small pulmonary arteries, and induce stimulation of cardiac muscle with increased cardiac output and the promotion of mild diuresis. It has been postulated that these actions may be related to the antagonism of adenosine receptors.
Combinations of ibuprofen with caffeine have been disclosed. See U.S. Pat. No. 4,851,444 which broadly discloses the combination of (S)-ibuprofen and several additional active ingredients including caffeine; 4,587,249 discloses the combination of ibuprofen and caffeine; See also 4,567,183; 4,558,051; 4,486,436; 4,464,376; 4,656,177; 4,777,174. There is a need to employ a compound with faster acting and enhanced analgesic capability as well as enhanced solubility such as (S)-ibuprofen-(S)-lysine substantially free of (R)- ibuprofen in combination with a xanthine derivative such as caffeine to more effectively treat and prevent the pain and discomfort associated with headaches or other aches and pains. The present invention provides both faster onset and enhanced relief of aches and pains associated with the head and body.
DETAILED DESCRIPTION OF THE INVENTION
This invention claims pharmaceutical compositions for use in the treatment of pain and inflammation. The composition comprises:
(i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)- lysine; and
(ii) an amount effective in enhancement of pain relief of caffeine.
This invention is also directed to a method of treating pain and inflammation in mammals, including humans, in need thereof, comprising administering to such organism:
(i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)- lysine; and(ii) an amount effective in enhancement of pain relief of caffeine.
This invention is further directed to a method of eliciting an onset hastened and enhanced response for the treatment of pain and inflammation in mammals, including humans, in need thereof, comprising administering to such organism: (i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)- lysine; and (ii) an amount effective in enhancement of pain relief of caffeine.
Substantially free of (R)-ibuprofen means that the ratio of (S)-ibuprofen to (R)-ibuprofen is at least 90:10.
Salts of (S)-ibuprofen include pharmaceutically acceptable salts such as alkali metals (sodium or potassium), alkaline earth metals (calcium), or salts with other metals such as magnesium, aluminum, iron, zinc, copper, nickel or cobalt.
Pharmaceutically acceptable salts of (S)-ibuprofen further include the amino acid salts, particularly the basic amino acids such as lysine or arginine. Specifically included within the composition of the instant invention is (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)- lysine.
The term mammals or mammalian organism includes but is not limited to man, dog, cat, horse and cow.
The term treatment encompasses the complete range of therapeutically positive effects associated with pharmaceutical medication including reduction of, alleviation of and relief from the symptoms or illness which affect the organism. (S)-ibuprofen may be prepared following the procedures disclosed in U.S. Patent 4,877,620. Metal salts of ibuprofen may be obtained by contacting a hydroxide, or carbonate with ibuprofen. Amino acid salts of ibuprofen may be obtained by contacting an amino acid in solution with ibuprofen. U.S. Patent No. 4,994,604 describes a process for the formation and resolution of (S)-ibuprofen-(S)-lysine that employs preferential crystallization to separate a pair of diastereomeric salts, (S)-ibuprofen-(S)-lysine and (R)-ibuprofen-(S)-lysine. The basic procedure involves (a) contacting (R),(S)-ibuprofen and (S)-lysine in an aqueous-organic solvent mixture; (b) separating any suspended solid from the mixture; and (c) cooling the clear mixture until the mixture is supersaturated with respect to each of the (S)-ibuprofen-(S)-lysine and (R)-ibuprofen-(S)-lysine salts; (d) contacting the supersaturated mixture with a slurry of (S)-ibuprofen-(S)-lysine in an aqueous-organic solvent; and (e) separating the formed crystalline (S)-ibuprofen-(S)-lysine.
Specifically, the racemic ibuprofen starting material is mixed with an organic solvent that is miscible with water. The (S)- lysine is mixed with water and the ibuprofen and lysine solutions are combined.
The mixture is agitated for a time period sufficient to crystallize all the salts, if any, in excess of the solubility limit. The suspended salts are separated to obtain a clear mother liquor which is generally saturated with respect to the diastereomeric salts (S)- ibuprofen-(S)-lysine and (R)-ibuprofen-(S)-lysine. Filtration may be employed to effect the separation. The liquor is then cooled to a temperature at which it is supersaturated with respect to each of the diastereomeric salts. It is preferred that the liquor be cooled to the point at which maximum supersaturation is obtained with respect to each salt without nucleation of either crystallizable species. Typically the temperature of the mother liquor must be lowered by about 5° C to reach maximum supersaturation without precipitation of either salt. However, the degree of cooling will depend on the particular solvent composition. The supersaturated liquor is then passed into a vessel containing a slurry of (S)-ibuprofen-(S)-lysine, hereafter referred to as the (S,S) salt, in the same solvent system employed above for the mixture of racemic ibuprofen and (S)-lysine. In the presence of the (S,S) salt crystals acting as a seed, the supersaturation of the (S,S)-salt in the feed liquor is released by the growth of further crystals of the (S,S)- salt. Conversely, there is little or no change in the (R)-ibuprofen-(S)- lysine supersaturation because the growth rate of the (R,S) crystals is essentially zero in the absence of any initial (R,S) salt seed. The (S,S) crystals are then separated by filtration or centrifugation and washed with aqueous-organic solvent to yield (S)-ibuprofen-(S)-lysine of purity approximating 98%.
The pharmaceutical compositions of the present invention are useful in the rapid and enhanced treatment of pain and inflammation. In particular, the (S)-ibuprofen-(S)-lysine combined with caffeine is useful for the treatment of pain, and inflammation. The utilization of (S)-ibuprofen and in particular (S)-ibuprofen-(S)-lysine in an analgesic/caffeine combination offers significant advantages over the combination of racemic ibuprofen and caffeine or (S)-ibuprofen and caffeine.
(S)-ibuprofen and in particular the lysine salt of (S)- ibuprofen provides a faster onset of pain and inflammation relief and an enhanced degree of relief compared to racemic ibuprofen. These benefits contribute to overall enhanced and faster relief of symptoms associated with headaches and other aches and pains when the (S)- ibuprofen -(S)-lysine is combined with a xanthine derivative such as caffeine.
The absence or reduction of (R)-ibuprofen also provides significant benefits. The allergic contraindications sometimes associated with ibuprofen administration are absent or reduced in a (R)-ibuprofen- free or substantially -free composition. An additional advantage may be that less metabolic energy will be used to convert the inactive (R)- ibuprofen to the active (S)-ibuprofen. In addition, a reduced burden may be placed on the urogenital system since administration of the pure (S)-ibuprofen eliminates the need to excrete the (R)-ibuprofen or its metabolites. The absence of the (R)-enantiomer also reduces or eliminates the incorporation of this molecule into fatty tissue. The renal burden and renal toxicities sometimes associated with racemic ibuprofen therapy may be reduced or eliminated in a (S)-ibuprofen composition that is substantially free of the (R) enantiomer.
Caffeine and xanthine alkaloids are known in the art and may be used in combination with (S)-ibuprofen (S)-lysine. Caffeine is well tolerated and has minimal side effects and thus advantageously may be used in the present invention in combination with (S)-ibuprofen (S)- lysine. The composition of (S)-ibuprofen-(S)-lysine with caffeine provides a combination which simultaneously and selectively provides enhanced relief from headaches, pain, and inflammation. This combination also has an advantage under circumstances where a mammalian organism requires enhanced pain relief and wakefulness or mental altertness.
The absence of inactive enantiomers, particularly (R)- ibuprofen provides for significant size and weight advantages in a combination dosage form, particularly a sustained release dosage form. Where a sustained release dosage of ibuprofen may have required 800 to 1000 mg, the employment of (S)-ibuprofen-(S)-lysine reduces the weight to 400 to 500 mg, and provides for a more practical size tablet for an ibuprofen/caffeine combination.
An effective amount of (S)-ibuprofen, or a salt thereof, for use in a unit dose composition of this invention may range from 50-800 mg of (S)-ibuprofen. The preferred amount of (S)-ibuprofen is about 100 to 400 mg. The amount of a salt such as (S)-ibuprofen-(S)-lysine is determined based on the amount of (S)-ibuprofen contained therein.
Caffeine is advantageously used in the present invention in combination with (S)-ibuprofen-(S)-lysine. The amount of caffeine used in the present invention in humans may range from 20 to 400 milligrams (mg). Advantageously, 32 to 65 mg is administered in combination with 100 to 400 mg of (S)-ibuprofen (S)-lysine. The combination claimed in the instant invention is advantageously admimstered orally. However, in patients with hypersecretory conditions, intractable ulcers, or in patients who are unable to take oral medication, the claimed combination may be administered intravenously in a suitable dosage within the limits described for oral treatment.
The present composition may be administered in the form of tablets, caplets, gelcaps, capsules, elixirs, syrups, or suspensions. For oral administration, the active ingredients may be admixed with a pharmaceutically acceptable diluent such as lactose, sucrose, cellulose, dicalcium phosphate, calcium sulfate, mannitol, and, in a liquid composition, ethyl alcohol. Acceptable emulsifying or suspending agents such as PVP, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, guar gum, agar, bentonite, carboxymethylcellulose sodium, polyethylene glycol and waxes, may also be admixed with the active components. Where necessary, lubricants such as magnesium stearic acid talc or magnesium stearate, and disintegrators or superdisintegrators such as starch, sodium starch glycolate or cross-linked PVP may also be included. Electrolytes such as dicalcium phosphate, sodium benzoate, sodium acetate and sodium chloride may also be used.
The active components may also be formulated in sustained release or effervescent formulations. These formulations depending upon whether they are sustained release or effervescent may be employed in oral, dermal, rectal or vaginal administrations. The sustained release formulations also include layered formulations which provide for distinct release ratio and thus may be more effective in allowing for short and long term relief.
The following examples illustrate the compositions of the present invention which may be readily prepared and as such are not to be considered as limiting the invention set forth in the claims.
EXAMPLE 1
(SVIbuprofen lvsine/caffeine Tablet
(S)-ibuprofen-(S)-lysine 342 mg caffeine 65 mg
PVP 15 mg
Avicel PHlOl 40 mg
Magnesium Stearate 4 mg
EXAMPLE 2 (SVIbuprofen lvsine/caffeine Tablet
(S)-ibuprofen-(S)-lysine 342 mg caffeine 20 mg
PVP 15 mg
Avicel PHlOl 40 mg
Magnesium Stearate 4 mg EXAMPLE 3 (SVIbuprofen lvsine/caffeine Sustained Release
(S)-ibuprofen-(S)-lysine 400 mg caffeine 65 mg
PVP 30 mg
Avicel PH101 80 mg
Magnesium Stearate 8 mg
Methocel E10MCR 66 mg Methocel K100MLV 200 mg
EXAMPLE 4 (SVIbuprofen (S Vlvsine/caffeine Sustained Release
(S)-ibuprofen-(S)-lysine 400 mg caffeine 200 mg
PVP 30 mg
Avicel PHlOl 80 mg
Magnesium Stearate 8 mg
Methocel E10MCR 66 mg
Methocel K100MLV 200mg
EXAMPLE 5 (SVIbuprofen-fSVlvsine/caffeine Solution
(S)-ibuprofen-(S)-lysine 342 mg caffeine 65mg g.s. syrup 5 ml
EXAMPLE 6 (SVIbuprofen-CSVlvsine/caffeine Solution
(S)-ibuprofen-(S)-lysine 342 mg caffeine 200 mg g.s. syrup 5 ml

Claims

WHAT IS CLAIMED IS:
1. A pharmaceutical composition for use in the treatment of pain and inflammation and the enhancement of pain relief in mammals, including humans comprising:
(i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)- lysine; and
(ii) an amount effective in the enhancement of pain relief of caffeine.
2. The composition of Claim 1 comprising at least 50 mg of (S)-ibuprofen-(S)-lysine.
3. The composition of Claim 1 comprising between 20-400 mg of caffeine.
4. The composition of Claim 1 comprising 100-400 mg of (S)-ibuprofen-(S)-lysine and 32-65 mg of caffeine.
5. A method of treating pain and inflammation and enhancing pain relief in a mammalian organism in need of such treatment, comprising administering to such organism:
(i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)- lysine; and
(ii) an amount effective in the enhancement of pain relief of caffeine.
6. A method according to Claim 5 wherein the composition administered to a mammalian organism in need thereof comprises:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine substantially free of (R)-ibuprofen ; and
(ii) an amount effective in the enhancement of pain relief of caffeine.
7. A method of eliciting an onset enhanced and hastened response or the treatment of pain and inflammation and the enhancement of pain relief in a mammalian organism in need of such treatment, comprising administering to such organism:
(i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)- lysine; and
(ii) an amount effective in the enhancement of pain relief of caffeine.
8. A method according to Claim 7 wherein the composition administered to a mammalian organism in need thereof comprises:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine substantially free of (R)-ibuprofen ; and
(ii) an amount effective in the enhancement of pain relief of caffeine.
9. A method of reducing the side effects associated with the administration of a racemic ibuprofen/caffeine combination which comprises the administration of:
(i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)- lysine; and (ii) an amount effective in the enhancement of pain relief of caffeine.
10. A method according to Claim 9 wherein the composition administered to a mammalian organism in need thereof comprises:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine substantially free of (R)-ibuprofen; and
(ii) an amount effective in the enhancement of pain relief of caffeine.
11. A method of reducing the size and weight of a pharmaceutically effective amount of an ibuprofen/caffeine combination dosage form which comprises combining
(i) an analgesically and anti-inflammatory effective amount of a salt of (S)-ibuprofen substantially free of (R)-ibuprofen wherein the salt is selected from (S)-ibuprofen-(S)-lysine and (S)-ibuprofen-(R)- lysine; and
(ii) an amount effective in the enhancement of pain relief of caffeine.
12. A method according to Claim 11 wherein the composition administered to a mammalian organism in need thereof comprises:
(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen-(S)-lysine substantially free of (R)-ibuprofen ; and
(ii) an amount effective in the enhancement of pain relief of caffeine.
PCT/US1993/008896 1992-09-29 1993-09-21 Ibuprofen-caffeine combinations WO1994007471A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP93922264A EP0663819A4 (en) 1992-09-29 1993-09-21 Ibuprofen-caffeine combinations.
JP6509126A JPH08501796A (en) 1992-09-29 1993-09-21 Ibuprofen-caffeine formulation
AU51328/93A AU5132893A (en) 1992-09-29 1993-09-21 Ibuprofen-caffeine combinations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95342392A 1992-09-29 1992-09-29
US953,423 1992-09-29

Publications (1)

Publication Number Publication Date
WO1994007471A1 true WO1994007471A1 (en) 1994-04-14

Family

ID=25493974

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/008896 WO1994007471A1 (en) 1992-09-29 1993-09-21 Ibuprofen-caffeine combinations

Country Status (6)

Country Link
EP (1) EP0663819A4 (en)
JP (1) JPH08501796A (en)
AU (1) AU5132893A (en)
CA (1) CA2144152A1 (en)
MX (1) MX9306005A (en)
WO (1) WO1994007471A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007079A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agents and caffeine
US5599969A (en) * 1992-12-02 1997-02-04 The Boots Company Plc Process of resolving phenylpropionic acids using α-methylbenzylamine
JPH0987174A (en) * 1995-09-26 1997-03-31 Kobayashi Pharmaceut Co Ltd Analgesic and anti-inflammatory composition
WO2000041680A1 (en) * 1999-01-14 2000-07-20 Knoll Aktiengesellschaft Pharmaceutical mixture comprising a combination of a profen and other active compounds
US20170209404A1 (en) * 2006-07-09 2017-07-27 Techfields Pharma Co., Ltd. High penetration compositions and uses thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170252346A1 (en) * 2014-08-28 2017-09-07 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for the treatment of acute tooth or jaw pain

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420483A (en) * 1982-07-22 1983-12-13 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4681897A (en) * 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8764191A (en) * 1990-09-28 1992-04-28 Mcneill-Ppc Inc. Ibuprofen-antihistamine combinations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4420483A (en) * 1982-07-22 1983-12-13 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising ibuprofen and methods of using same
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4681897A (en) * 1984-01-16 1987-07-21 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4812446A (en) * 1984-01-16 1989-03-14 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP0663819A4 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5599969A (en) * 1992-12-02 1997-02-04 The Boots Company Plc Process of resolving phenylpropionic acids using α-methylbenzylamine
WO1995007079A1 (en) * 1993-09-07 1995-03-16 The Procter & Gamble Company Compositions containing an amino acid salt of propionic acid non-steroidal anti-inflammatory agents and caffeine
JPH0987174A (en) * 1995-09-26 1997-03-31 Kobayashi Pharmaceut Co Ltd Analgesic and anti-inflammatory composition
WO2000041680A1 (en) * 1999-01-14 2000-07-20 Knoll Aktiengesellschaft Pharmaceutical mixture comprising a combination of a profen and other active compounds
US20170209404A1 (en) * 2006-07-09 2017-07-27 Techfields Pharma Co., Ltd. High penetration compositions and uses thereof
US9872846B2 (en) * 2006-07-09 2018-01-23 Techfields Pharma Co., Ltd. High penetration compositions and uses thereof

Also Published As

Publication number Publication date
MX9306005A (en) 1995-01-31
EP0663819A4 (en) 1998-05-27
AU5132893A (en) 1994-04-26
CA2144152A1 (en) 1994-04-14
EP0663819A1 (en) 1995-07-26
JPH08501796A (en) 1996-02-27

Similar Documents

Publication Publication Date Title
US5164398A (en) Ibuprofen-antitussive combinations
US4571400A (en) Dihydrocodeine/ibuprofen pharmaceutical compositions and method
RU2125873C1 (en) Analgetic composition and a method of analgetic effect attainment in human
US5206029A (en) Medicament and its production and use in the treatment of pain, inflammation and fever in man and animals
JP2957701B2 (en) Antipyretic and analgesic methods and compositions comprising optically pure R-ketorolac
US7141606B2 (en) Gabapentin analogues for sleep disorders
EP0663839A1 (en) Ibuprofen-h 2? antagonist combinations
US4587252A (en) Hydrocodone/ibuprofen pharmaceutical compositions and method
US5288507A (en) Ibuprofen antacid combinations
US5260337A (en) Ibuprofen-muscle relaxant combinations
JPH0670057B2 (en) Guanine derivative crystalline monohydrate, method for producing the same and antiviral agent containing the same
JPH03206064A (en) S(plus)-ibuprofen-l-amino acid and s(plus)- ibuprofen-d-amino acid as a pain-killing agent for producing an immediate and augmented analgesic efficacy
WO1994007471A1 (en) Ibuprofen-caffeine combinations
WO1994003209A1 (en) Dexibuprofen/antacid/simethicone combinations
US5519057A (en) Ibuprofen-containing medicament
EP0577757A1 (en) Ibuprofen-decongestant combinations
US20100298258A1 (en) Analgesic compositions
CA2202425A1 (en) A novel anti-spasmodic and antiinflammatory composition and a process for the manufacture thereof
US4120976A (en) Treatments for arthritis and cast dermatitis
WO1992005786A1 (en) Ibuprofen-diuretic combinations
JP3083568B2 (en) Anti-rheumatic drug
US4537907A (en) Hypnotic composition and method of inducing sleep
Kato et al. Anaphylactic reaction induced by diclofenac
JPS58135861A (en) N,n'-bis-(5-oxo-1-methyl-pyrrolidine-2-yl-acetic acid) hydrazide, its preparation, and its use as drug

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU BB BG BR BY CA CZ FI HU JP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2144152

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1993922264

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1993922264

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 1995 406938

Country of ref document: US

Date of ref document: 19950728

Kind code of ref document: A

WWW Wipo information: withdrawn in national office

Ref document number: 1993922264

Country of ref document: EP